American Diabetes Association GUIDELINES Apps - Institutional

Hyperglycemia 2012 ADA v2_eViewer

American Diabetes Association (ADA) GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/143157

Contents of this Issue

Navigation

Page 10 of 15

Advantages Disadvantages Cost •  Extensive experience •  No weight gain •  No hypoglycemia •  Likely ↓ CVD events (UKPDS) •  Gastrointestinal side effects (diarrhea, abdominal cramping) •  Lactic acidosis risk (rare) •  Vitamin B12 deficiency •  Multiple contraindications: CKD, acidosis, hypoxia, dehydration, etc. •  Hypoglycemia •  Weight gain •  ? Blunts myocardial ischemic preconditioning •  Low durability •  Hypoglycemia •  Weight gain •  ? Blunts myocardial ischemic preconditioning •  Frequent dosing schedule •  Weight gain •  Edema/heart failure •  Bone fractures •  ↑ LDL-C (rosiglitazone) •  ? ↑ MI (meta-analyses, rosiglitazone) •  ? ↑ Bladder cancer (pioglitazone) Low •  Generally modest HbA1c efficacy •  Gastrointestinal side effects (flatulence, diarrhea) •  Frequent dosing schedule Moderate •  Generally modest HbA1c efficacy •  Urticaria/angioedema •  ? Pancreatitis High •  Generally modest HbA1c efficacy •  Constipation •  ↑ Triglycerides •  May ↓ absorption of other medications High •  Extensive experience •  ↓ Microvascular risk (UKPDS) •  ↓ Postprandial glucose excursions •  Dosing flexibility •  No hypoglycemia •  Durability •  ↑ HDL-C •  ↓ Triglycerides (pioglitazone) •  ? ↓ CVD events (ProACTIVE, pioglitazone) •  No hypoglycemia •  ↓ Postprandial glucose excursions •  ? ↓ CVD events (STOP-NIDDM) •  Nonsystemic •  No hypoglycemia •  Well tolerated •  No hypoglycemia •  ↓ LDL-C Low High Highd Continued on next page. 9

Articles in this issue

Archives of this issue

view archives of American Diabetes Association GUIDELINES Apps - Institutional - Hyperglycemia 2012 ADA v2_eViewer